Lung Cancer

Lung cancer, particularly non-small cell lung cancer (NSCLC), is marked by high mortality rates due to late detection, resistance to therapy, and metastasis. Elevated levels of ALDH1A3 in lung tumors drive cancer cell adaptability and survival, presenting an opportunity for precision-targeted therapies like VE3 to enhance treatment efficacy.